Niva Bupa IPO GMP Today: Subscription Status, Grey Market Premium, and More

Niva Bupa IPO GMP Today

The Niva Bupa IPO GMP remains flat on day two of subscription, as investors carefully evaluate this significant entry into India’s health insurance sector. With the subscription window closing on November 11, 2024, let’s dive into the current market sentiment and subscription status of this eagerly watched public offering.

Niva Bupa IPO GMP Today: Current Subscription Status

As of 11:15 AM on Friday, November 8, 2024, the IPO has achieved a 71% subscription rate, with investors bidding for 12.20 crore shares against the 17.28 crore shares offered. The retail segment has shown particularly strong interest, with the retail quota being fully subscribed. Qualified Institutional Buyers (QIBs) have subscribed 0.79 times their portion, while Non-Institutional Investors (NIIs) have reached 0.35 times subscription.

IPO Details and Timeline

The company has set the price band at ₹70-74 per share, with a minimum lot size of 200 shares. Key dates include:

• Subscription Closing: November 11, 2024
• Allotment Date: November 12, 2024
• Demat Credit: November 13, 2024
• Listing Date: November 14, 2024 (BSE and NSE)

Grey Market Performance

The grey market premium (GMP) currently stands at nil, indicating neutral market sentiment. This flat GMP suggests investors are taking a measured approach, focusing on the company’s fundamentals rather than speculative gains.

Company Background

Niva Bupa Health Insurance represents a strategic partnership between the UK-based Bupa Group, bringing 70 years of healthcare expertise, and Fettle Tone LLP, managed by True North, a leading Indian private equity fund. Since its establishment in 2008, the company has built a strong reputation in providing comprehensive health insurance solutions.

Expert Opinions

Leading brokerages including Anand Rathi Research Team, Swastika Investmart, and Bajaj Broking have expressed positive long-term outlook for the IPO. Their recommendations are based on:

• Strong market position
• Experienced management team
• Growing health insurance sector
• Robust business model

For investors still contemplating participation, the remaining subscription window offers time to evaluate this opportunity in India’s growing health insurance sector. While the flat GMP might concern some, the strong retail subscription and positive broker recommendations suggest confidence in the company’s long-term prospects.

Read More:  SBI Share Price: Secret Behind SBI Q2 Profit 28% Growth

FAQs